IRC Section 174

Internal Revenue Code Section 174 requires the capitalization of research costs for tax purposes, directly forming the starting point for New York’s R&D tax credits by defining the eligible expenditure base. In the context of New York State, this federal rule determines the “Entire Net Income” upon which state corporate taxes and incentives are layered.

The Foundations of Research and Experimental Expenditure Accounting

The Internal Revenue Code (IRC) Section 174 has served as the bedrock for innovation-related tax accounting since its inception in 1954. At its core, Section 174 was designed to provide a uniform method for treating research and experimental (R&E) expenditures, thereby reducing the ambiguity that previously surrounded whether such costs were current business expenses or long-term capital investments. For decades, the law incentivized American innovation by allowing businesses to immediately deduct these costs in the year they were incurred, supporting cash flow for research-heavy organizations. This immediate expensing was a fundamental assumption in the business models of New York’s technology and life sciences sectors.

The definition of R&E expenditures under Section 174 is notably broader than the definition of “qualified research” under Section 41, the latter of which governs the federal R&D tax credit. While Section 41 focuses primarily on direct costs such as wages, supplies, and contract research, Section 174 encompasses all costs incident to the development or improvement of a product, process, formula, invention, or software. This expansive scope includes not only direct research labor but also indirect costs, overhead such as rent and utilities for research facilities, patent legal fees, and depreciation on equipment used in the laboratory. For New York taxpayers, understanding this distinction is the first step in coordinating federal deductions with state-level credits.

The legislative landscape shift began with the Tax Cuts and Jobs Act (TCJA) of 2017. The TCJA introduced a mandatory capitalization and amortization regime for specified research or experimental (SRE) expenditures for tax years beginning after December 31, 2021. Under this regime, businesses were no longer permitted to expense R&E costs; instead, domestic costs were required to be amortized over five years, while foreign research costs were subjected to a 15-year amortization period. This mandatory deferral of deductions created a significant “timing difference” that resulted in a sudden increase in taxable income for New York firms, often regardless of whether those firms were profitable in an economic sense.

The Federal Restoration: OBBBA and Section 174A

Recognizing the competitive disadvantage and cash-flow strain imposed by mandatory amortization, the federal government enacted the One Big Beautiful Bill Act (OBBBA) on July 4, 2025. The OBBBA fundamentally restored the status quo for domestic innovation by introducing Section 174A, which permanently allows taxpayers to fully expense domestic R&E expenditures in the year they are incurred, effective for tax years beginning after December 31, 2024. This restoration simplifies the federal tax landscape once more, though it maintains the 15-year amortization requirement for foreign R&E, thus discouraging the offshoring of research activities.

The OBBBA also provides critical transition rules and retroactive relief that are of vital importance to New York’s startup ecosystem. Small business taxpayers—defined as those with average annual gross receipts of $31 million or less over the three preceding years—may elect to retroactively apply the expensing rules to the 2022, 2023, and 2024 tax years. This allows these eligible entities to amend prior returns and claim substantial refunds for taxes paid during the amortization years. For larger businesses, the law permits a “catch-up” deduction, where unamortized domestic R&E costs from 2022–2024 can be accelerated and deducted either entirely in 2025 or ratably over the 2025 and 2026 tax years.

New York State’s Conformity Mechanism

New York State maintains a “rolling conformity” approach to the Internal Revenue Code for its corporate franchise tax, governed by Article 9-A. This means that when federal law changes the calculation of Federal Taxable Income (FTI), those changes automatically flow through to the New York tax base unless the state legislature affirmatively decouples from specific provisions. Consequently, New York conformed to the TCJA’s amortization requirement in 2022 and will automatically conform to the OBBBA’s restoration of expensing in 2025.

For New York corporations, the starting point for calculating tax is “Entire Net Income” (ENI), which is defined as federal taxable income with certain state-specific modifications. Because Section 174 (and the new Section 174A) dictates the timing of R&D deductions at the federal level, it directly impacts the ENI reported on New York Form CT-3 or CT-3-S. During the 2022–2024 period, the lack of a full Section 174 deduction at the federal level meant that New York ENI was correspondingly higher, increasing the state tax liability for many innovative firms.

The interaction between federal Section 174 and state-level credits is the primary area where New York revenue office guidance becomes essential. While the state follows federal rules for the deduction, it provides its own distinct framework for credits. A key insight into this relationship is that New York’s tax credits are typically “refundable” for new businesses, meaning that even if the Section 174 amortization rules increased a company’s tax liability, the state’s credits could often be used to generate a cash refund, mitigating some of the federal-level burden.

Local State Revenue Office Guidance: The Department of Taxation and Finance

The New York State Department of Taxation and Finance (DTF) provides guidance through Technical Services Bureau Memoranda (TSB-M), administrative rules, and specific instructions for various credit forms. This guidance establishes the procedural requirements for claiming R&D incentives and clarifies the state’s interpretation of federal definitions.

Article 9-A and Article 22 Compliance

Taxpayers in New York are generally subject to either the corporate franchise tax (Article 9-A) or the personal income tax (Article 22), the latter applying to partners in partnerships, members of LLCs, and shareholders of New York S corporations. For both articles, the state requires that any federal deduction for Section 174 expenses be reflected in the state return. DTF guidance emphasizes that a taxpayer cannot choose to amortize for state purposes if they have expensed for federal purposes, or vice-versa, unless a specific state decoupling provision exists.

Form-Level Guidance and Instructions

The primary mechanism for claiming research-related incentives is through the completion of specific credit forms which are attached to the annual tax return. Each form comes with detailed instructions that function as the revenue office’s local guidance:

• Form CT-633 / IT-633 (Excelsior Jobs Program): These instructions clarify that the credit is only available to participants in the program who have received a “Certificate of Tax Credit” from Empire State Development (ESD). The instructions define “net new jobs” and “qualified investment” with precision, noting that expenses used as the basis for this credit cannot be used for any other credit.
• Form DTF-621 / DTF-622 (QETC Credits): These forms provide the methodology for calculating the Qualified Emerging Technology Company (QETC) Employment and Capital tax credits. Guidance here focuses on the requirement to meet R&D-to-sales ratios, which are benchmarked against National Science Foundation (NSF) data.
• Form CT-631 / IT-631 (Security Officer Training/QETC): While some versions of these forms apply to security training, they are part of a broader suite of incentive forms that require a specific certificate from the allocating agency.

Audit and Record-Keeping Guidance

New York State is known for rigorous audit procedures regarding R&D credits. Local guidance, supported by case law and TSB-Ms, mandates that taxpayers maintain contemporaneous records to prove that activities were conducted in New York and met the federal “Four-Part Test” for research. This includes maintaining project records, lab notes, payroll records, and general ledgers that explicitly link costs to specific research projects. DTF guidance explicitly warns that “funded research”—research where the taxpayer does not retain substantial rights or is fully reimbursed by a third party—is generally ineligible for state credits.

The Excelsior Research and Development Tax Credit

The Excelsior Jobs Program represents New York’s most comprehensive incentive for high-growth sectors. The Research and Development component of this program is calculated based on federal standards but restricted to New York activities.

The 50% Match Mechanism

The Excelsior R&D credit is unique in that it is equal to 50% of the portion of the taxpayer’s federal research and development tax credit (calculated under Section 41) that is attributable to New York State expenditures. This creates a direct causal link: if a company fails to qualify for the federal credit, it is automatically disqualified from the Excelsior R&D credit.

Expenditure Caps and Green Project Bonuses

The state imposes a ceiling on this benefit to manage fiscal impacts. The credit is capped at 6% of the qualified research expenditures (QREs) incurred in New York. However, in alignment with New York’s Climate Leadership and Community Protection Act, projects designated as “green projects” or “green CHIPS projects” (related to semiconductor manufacturing) receive an enhanced cap of 8%.

Empire State Development (ESD) Certification

Unlike standard tax deductions, the Excelsior credits are discretionary. A business must apply to its regional ESD office through the Consolidated Funding Application (CFA) portal. Once approved, the business enters into a “Performance Agreement” with the state, agreeing to meet specific job and investment targets. Only after submitting a performance report at the end of the year and receiving a certificate of tax credit can the taxpayer claim the incentive on their DTF filing.

The Life Sciences Research and Development Tax Credit

Designed specifically for the biotechnology and pharmaceutical industries, the Life Sciences credit operates independently of the Excelsior program and offers a simpler, fixed-rate calculation.

Tiered Rates for Small vs. Large Teams

The Life Sciences credit prioritizes smaller, early-stage research teams by offering higher rates for lower headcounts:

• 20% Rate: Available to companies employing fewer than 10 persons in New York State during the tax year.
• 15% Rate: Available to companies with 10 or more employees.

Key Limitations and Divergence from Federal Law

While the Life Sciences credit uses federal concepts to define research, it excludes “contract research” from the credit base. At the federal level, a company can generally claim 65% of fees paid to third-party researchers. New York’s Life Sciences credit, however, only allows for in-house wages and supplies. This highlights a critical planning point: a biotech firm using a Contract Research Organization (CRO) will see a benefit on their federal Section 41 credit and their New York Excelsior credit, but not on the New York Life Sciences credit. Additionally, this credit is capped at $500,000 per year and can only be claimed for three consecutive years.

Qualified Emerging Technology Company (QETC) Credits

The QETC framework is aimed at “emerging” companies with $10 million or less in annual product sales. It provides two distinct credits that rely on R&D activity.

The QETC Employment Credit

This refundable credit offers $1,000 for each net new employee, provided the company’s workforce is at least 101% of its base-year employment. To qualify as a QETC for this credit, the company must perform R&D in New York and demonstrate that its ratio of R&D funds to net sales equals or exceeds the NSF average.

The QETC Capital Tax Credit

This credit incentivizes investment in certified QETCs. Taxpayers who make a qualified investment receive a credit of:

• 10% for investments with a useful life of four years.
• 20% for investments with a useful life of nine years.

The “useful life” in this context refers to the duration the investor holds the interest in the QETC, reflecting a state policy aimed at encouraging long-term capital stability for tech startups.

Statistical Overview: R&D in the New York Economy

The importance of Section 174 and state R&D credits is reflected in the massive scale of investment in the region. According to National Science Foundation (NSF) data, New York is one of the top five states for state government expenditures for extramural R&D, with over $168 million in state agency spending alone for FY 2024. This is part of a broader $2.5 billion national trend in state-funded R&D performance.

Furthermore, federal obligations for R&D in New York are substantial. In 2025, federal obligations in the state totaled over $251.9 billion across all programs, with hundreds of millions specifically directed toward physical, engineering, and life sciences research (NAICS 541712 and 541715). The Life Sciences Research and Development Tax Credit program, which attracts significant activity in New York City’s biotech corridor, has seen over $50 million allocated since 2018. These statistics underscore the high stakes for New York businesses in maintaining compliance with Section 174, as even a minor accounting error can impact eligibility for millions in state and federal support.

New York S-Corporation Nuances and the Fixed Dollar Minimum Tax

New York S corporations are subject to unique rules under Article 9-A. While the income and deductions (including Section 174) pass through to the shareholders’ personal tax returns, the S corporation itself must pay a “Fixed Dollar Minimum” (FDM) tax at the entity level.

For QETCs and “Qualified New York Manufacturers,” the FDM tax is significantly lower than for general business taxpayers. For instance, a QETC with New York receipts between $500,000 and $1,000,000 pays an entity-level tax of only $225, compared to $300 for a standard S corp. This creates a further incentive for companies to maintain their “Emerging Technology” status through consistent R&D spending as defined by Section 174.

S-Corp Passthrough of Credits

Any credits earned by a New York S corporation, such as the Excelsior or QETC credits, are calculated at the entity level but passed through to shareholders on Form CT-34-SH. The shareholders then claim their pro rata share of the credit on their personal income tax returns (Form IT-201 or IT-203) using the equivalent IT-credit forms.

Comprehensive Integrated Example: “Hudson River Quantum Dynamics”

To illustrate the interplay of these laws, consider “Hudson River Quantum Dynamics” (HRQD), a New York-based software and hardware engineering firm.

Company Profile (2025 Tax Year)

• Entity Type: C Corporation (Article 9-A).
• Industry: Quantum Computing (QETC and Scientific R&D).
• Revenue: $8,000,000 (qualifies as a “small business” under the $31M test).
• Personnel: 12 full-time employees in New York.
• Certification: Approved for the Excelsior Jobs Program.

Step 1: Federal Section 174A Calculation

In 2025, HRQD incurs $3,000,000 in domestic R&E expenditures. Under the new OBBBA Section 174A, they choose to immediately deduct the full $3,000,000. Because they are a small business, they also make the SBR (Small Business Retroactivity) election and amend their 2022–2024 returns to claim refunds on previously capitalized costs.

Step 2: New York Entire Net Income (ENI)

New York rolling conformity means HRQD’s state return starts with Federal Taxable Income. The $3,000,000 deduction for R&E costs reduces their ENI dollar-for-dollar.

Step 3: Calculating New York State Credits

HRQD identifies $2,000,000 in Qualified Research Expenses (QREs) specifically for the New York portion of their federal Section 41 credit.

• Federal R&D Credit: Assuming a 10% net credit rate, their federal credit is $200,000.
• Excelsior R&D Credit: They claim 50% of the federal NY-related credit ($200,000 * 50% = $100,000).
• Cap Check: $100,000 is well below the 6% cap of New York QREs ($2,000,000 * 6% = $120,000). If this were a “Green Project,” the cap would be $160,000.
• Excelsior Jobs Credit: As they created 5 net new jobs at $100,000 salary each, they claim 6.85% of those wages ($500,000 * 6.85% = $34,250).

Step 4: Net Tax Benefit

• Total State Credits: $134,250 ($100,000 R&D + $34,250 Jobs).
• Status: Because these are refundable credits, if HRQD’s tax liability is only $10,000, the state will issue a check for the remaining $124,250.

The Empire Innovation Act and Future Legislative Trends

New York is actively considering further enhancements to its R&D framework to counter the negative impacts of previous federal amortization rules. Senate Bill S303, known as the “Empire Innovation Act,” aims to expand the Excelsior R&D credit. A critical provision of this proposed legislation allows for the calculation of credits even if the federal R&D credit were to expire, using the 2009 federal credit structure as a permanent state-level benchmark.

This legislative activity indicates a growing trend of “state-level solutions” to federal disincentives. By decoupling the definition of the credit from current federal availability while maintaining the Section 174 expenditure base, New York aims to provide a more predictable environment for long-term research cycles. Additionally, the state has launched programs like CATALIST NY to support startups that have completed incubator programs, further reducing the cost of hiring and research.

Final Thoughts: Synthesis and Strategic Recommendations

The interaction of IRC Section 174 and New York’s R&D tax incentives creates a complex but highly rewarding environment for innovative businesses. The 2025 restoration of domestic expensing via the OBBBA has re-aligned federal and state interests, allowing New York’s rolling conformity to simplify the path toward lower taxable income for research-driven organizations.

To maximize these benefits, New York businesses should adopt a multi-faceted strategy:

1. Prioritize Domestic Activities: The tax code now heavily penalizes foreign research through 15-year amortization while rewarding domestic spending with immediate expensing and lucrative state credits.
2. Evaluate Small Business Retroactivity: Eligible firms should immediately review 2022–2024 filings to unlock cash refunds through amended returns.
3. Align with Strategic Goals: Participation in the Excelsior Jobs Program provides the most robust multi-year support but requires early engagement with Empire State Development and careful tracking of job targets.
4. Rigorous Documentation: The combination of federal capitalization rules and New York’s high audit standards makes contemporaneous record-keeping non-negotiable.

As New York continues to evolve its local tax policy through initiatives like the Empire Innovation Act, the state solidifies its position as a premier destination for global research and development. Success in this landscape requires a nuanced understanding of how a single federal code section—174—ripples through every level of the state’s fiscal architecture.